Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 24, Art. 14 (pp. 166-175)    |    2023       

»

Preclinical screening for the efficacy and safety of k-opiate analgesics based on their neurotoxic profile

Ivanov D.G., Afonkina E. A., Lysenko Y. N., Khromov R. N., Nikiforov A. S., Subbotina S. N., Sitnikov D. K.

Federal State Budgetary Institution ?State Research Testing Institute of Military Medicine? of the Ministry of Defense of the Russian Federation

Brief summary

The article developed a scheme for preclinical screening of the efficacy and safety of κ-opiate analgesics based on their neurotoxic profile. Doses of drugs that cause 50%, 16% and 84% effect are determined. The possibility of screening efficacy and safety, as well as the possibility of identifying κ-opiate analgesics based on the symptom complex on their neurotoxic action. Sedation, hypothermia, diuresis, in the absence of catalepsy and the Straub reaction were significant for assessing the difference between κ-opiate analgesics and other symptoms. The study of the neurotoxic profile of opiate analgesics in the experiment allows us to compare the efficacy and safety of opiate analgesics in order to select the most promising drugs.


Key words

toxicity, κ-opiate analgesics, preclinical trials

Reference list

1. Bikov V.N., Anohin A.G., Chepyr S.V., Ivanov I.M., Pokrovskaya L.A., Nazarov G.V., Galan S.E., Myradov M.M. Issledovanie psiholepticheskih effektov k-opioidnih agonistov // Toksikologicheskii vestnik. 2011. 3. S. 13-16.


2. Lovell K.M., Frankowski K.J., Stahl E.L., Slauson S.R., Yoo E., Prisinzano T.E., Aubé J., Bohn L.M. Structure Activity Relationship Studies of Functionally Selective Kappa Opioid Receptor (KOR) Agonists that Modulate ERK ½ Phosphorylation While Preserving G Protein Over β-Arrestin 2 Signaling Bias // ACS Chem. Neurosci. 2015. P. 1411-1419. DOI: 10.1021/acschemneuro.5b00092.


3. Butelman E.R., Ko M.C.H., Traynor J.R., Vivian J.A., Kreek M.J., Woods J.H. GR89,696: a potent - opioid agonist with subtype selectivity in rhesus monkeys // The journal of pharmacology and experimental therapeutics. 2001. V. 298. P. 1049-1059.


4. Lemos J.C., Chavkin C. Kappa Opioid Receptor Function // The Receptors 23. The Opiate Receptors by ed. G.W. Pasternak. Springer Science+Business Media. 2011. P.265-306.


5. Walsh S.L., Strain E.C., Abreu M.E. Bigelow G.E. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans // Psychopharmacology. 2001. V.157. P.151-162.


6. Brust T.F., Morgenweck J., Kim S.A., Rose J.H., Locke J.L., Schmid C.L., Zhou L., Stahl E.L., Cameron M.D., Scarry S.M., Aubé J., Jones S.R., Martin T.J., Bohn L.M. Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria // Science Signaling. 2016. Vol. 9 DOI: 10.1126/scisignal.aai8441.


7. Ehrich J.M., Messinger D.I., Knakal C.R., Kuhar J.R., Schattauer S.S., Bruchas M.R., Zweifel L.S., Kieffer B.L., Phillips P.E.M., Chavkin C. Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons // The journal of neuroscience. 2015. V. 35. N.37. P. 12917-12931.


8. Bruchas M.R., Chavkin C. Kinase cascades and ligand-directed signaling at the kappa opioid receptor // Psychopharmacology. 2010. V. 210. P. 137-147.


9. Dunn A.D., Reed B., Guariglia C., Dunn A.M., Hillman J.M., Kreek M.J. Structurally Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice // International Journal of Neuropsychopharmacology. 2018. V. 21. N. 9. P. 847-857.


10. Fride E.,Perchuk A., Hall F.S., Uhl G.R., Onaivi E.S. Behavioral Methods in Cannabinoid Research// In:Marijuana and Cannabinoid Research: Methods and Protocols/ ed. E.S.Onaivi.Totowa, NJ: Humana Press Inc. 2006. P.269-290


11. White K.L., Alex P. Scopton, Marie-Laure Rives, Ruslan V. Bikbulatov, Prabhakar R. Polepally, Peter J. Brown, Terrance Kenakin, Jonathan A. Javitch, Jordan K. Zjawiony, and Bryan L. Roth identification of novel functionally selective k-opioid receptor scaffolds // Mol. Pharmacol. 2014. V.85. P. 83-90.


12. Byresh, Ya. Metodiki i osnovnie eksperimenti po izycheniu mozga i povedeniya / Ya. Byresh, O. Byreshova, Dj.P. Huston. M.: Visshaya shkola. 1991. 399 s.


13. Roux, S. Primary Observation (Irwin) testin rodents for assessing acute toxicity of a test agent and its effects on behavior and physiological function / S. Roux, E. Sablre, R.D. Porsolt // Current protocols in pharmacology. 2004. P. 1-23.


14. Hama A., Sagen J. Sustained antinociceptive effect of cannabinoid receptor agonist WIN 55,212-2 over time in rat model of neuropathic spinal cord injury pain // Journal of Rehabilitation Research & Development. 2009. V. 46. N. 1. P. 135-144.


15. Lei C., Sun X. Comparing lethal dose ratios using probit regression with arbitrary slopes // BMC Pharmacology and Toxicology, 2018. V. 19. P.61


16. Hudzik T.J., Maciag C., Smith, M.A., Caccese R., Pietras M.R., Bui K.H., Coupal M., Adam L., Payza K., Griffin A., Smagin G., Song D., Swedberg M.D.B., Brown W. Preclinical pharmacology of AZD2327- a highly selective agonist of the δ-opioid receptor // ASPET Journals. 2011.


17. Jutkiewicz E.M., Eller E.B., Folk J.E., Rice K.C., Traynor J.R., Woods J.H. -Opioid agonists: differential efficacy and potency of snc80, its 3-oh (snc86) and 3-desoxy (snc162) derivatives in sprague-dawley rats // The journal of pharmacology and experimental therapeutics. 2004. V. 309. P. 173-181.


18. Baker A.K., Meert T.F. Functional effects of systemically administered agonists and antagonists ofμ, δ, and κ opioid receptor subtypes on body temperature in mice // The journal of pharmacology and experimental therapeutics. 2002. V. 302. N. 3. P. 1253-1264.


19. Adams S.S., Bough R.G., Cliffe E.E., Lessel B., Mills R.F.N. Absorption, distribution and toxicity of ibuprofen // Toxicology and applied pharmacology. 1969. V.15. P. 310-330.


20. Pfeiffer A., Brantl V., Herz A., Emrich H.M. Psychotomimesis mediated by κ-opiate receptors // Science. 1986. V. 233. P. 774-776.


21. Walsh S.L., Strain E.C., Abreu M.E. Bigelow G.E. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans // Psychopharmacology. 2001. V.157. P.151-162.


22. Chappell P.B., Leckman J.F., Scahill L.D., Hardin M.T., Anderson G., Cohen D.J. Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette?s syndrome: a pilot study // Psychiatry res. 1993. V. 47. P. 267-280.